Lindsey Galbo

Lindsey Galbo


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2020 in Molecules
Verified
Journal Article
Open access
PDF file
NDNaresh Damuka
Naresh Damuka
PCPaul Czoty
Paul Czoty
ADAshley T. Davis
Ashley T. Davis
MNMichael A. Nader
Michael A. Nader
SNSusan H. Nader
Susan H. Nader
KSKiran Sai
Kiran Sai
Dysregulation of microtubules is commonly associated with several psychiatric and neurological disorders, including addiction and Alzheimer’s disease. Imaging of microtubules in vivo using positron emission tomography (PET) could provide valuable information on their role in the development of disease pathogenesis and aid in improving therapeutic regimens. We developed [11C]MPC-6827, the first brain-penetrating PET radiotracer to image microtubules in vivo in the mouse brain. The aim of the present study was to assess the reproducibility of [11C]MPC-6827 PET imaging in non-human primate brains. Two dynamic 0–120 min PET/CT imaging scans were performed in each of four healthy male cynomolgus monkeys approximately one week apart. Time activity curves (TACs) and standard uptake values (SUVs) were determined for whole brains and specific regions of the brains and compared between the “test” and “retest” data. [11C]MPC-6827 showed excellent brain uptake with good pharmacokinetics in non-human primate brains, with significant correlation between the test and retest scan data (r = 0.77, p = 0.023). These initial evaluations demonstrate the high translational potential of [11C]MPC-6827 to image microtubules in the brain in vivo in monkey models of neurological and psychiatric diseases.

27 August 2023 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Open access
LGLindsey Galbo
Lindsey Galbo
ADApril T. Davenport
April T. Davenport
PEPhillip M. Epperly
Phillip M. Epperly
PCPaul Czoty
Paul Czoty
Background: Chronic stress contribute to the development of alcohol use disorder (AUD). However, characterizing the role of chronic social stressors in the development of problematic drinking trajectories in humans is complicated by practical and ethical constraints. Group‐housed nonhuman primates develop social dominance hierarchies that represent a continuum of social experiences from enrichment in higher‐ranked (dominant) monkeys to chronic social stress in lower‐ranked (subordinate) individuals. This framework provides a translationally relevant model of chronic social stress that can be used to characterize its effects on vulnerability to AUD.Methods: Twelve male cynomolgus monkeys living in three social groups with established social dominance hierarchies were provided access to ethanol and water for 22 h/day, 4–5 days/week, for 1 year. Ethanol‐free periods (2‐ or 3‐day “weekends” or longer periods up to 10 days) were spent in social groups to maintain the stability of the social hierarchies. Observational studies conducted 6 months into the year of drinking assessed signs of ethanol withdrawal. After 1 year, monkeys were individually housed 24 h/day, 7 days/week for four consecutive weeks to examine the effect of eliminating the “weekends” spent socially housed.Results: Subordinate monkeys had significantly higher mean daily ethanol intakes than dominant monkeys across 1 year of open access. Subordinates also had higher intakes on the first day back drinking following ethanol‐free periods of 9–10 days. Moreover, during the last 4 weeks of open access, intakes on the first drinking day after an ethanol‐free weekend increased significantly in subordinate monkeys. This effect diminished when all monkeys were individually housed for 4 weeks, indicating that the increased intake in subordinates was driven by the social environment.Conclusions: These data demonstrate that social subordination, which is associated with chronic social stress, results in increased vulnerability to the development and maintenance of heavy drinking trajectories.

1 January 2021 in Brain Stimulation
Verified
Journal Article
Open access
CHColleen A Hanlon
Colleen A Hanlon
PCPaul W. Czoty
Paul W. Czoty
HSHilary R. Smith
Hilary R. Smith
PEPhillip M. Epperly
Phillip M. Epperly
LGLindsey Galbo
Lindsey Galbo

22 December 2023 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
LGLindsey Galbo
Lindsey Galbo
PEPhillip M. Epperly
Phillip M. Epperly
BBBruce E. Blough
Bruce E. Blough
ALAntonio Landavazo
Antonio Landavazo
SSSantiago J. Saldaña
Santiago J. Saldaña
PCPaul Czoty
Paul Czoty
The cognitive impairments that are often observed in patients with alcohol use disorder (AUD) partially contribute to the extremely low rates of treatment initiation and adherence. Brain acetylcholine receptors (AChR) mediate and modulate cognitive and reward-related behavior and their distribution can be altered by long-term heavy drinking. Therefore, AChRs are promising pharmacotherapeutic targets for treating the cognitive symptoms of AUD. In the present study, the pro-cognitive efficacy of two AChR agonists, xanomeline and varenicline, were evaluated in group-housed monkeys who self-administered ethanol for more than one year. The muscarinic AChR antagonist scopolamine was used to disrupt performance of a serial stimulus discrimination and reversal (SDR) task designed to probe cognitive flexibility, defined as the ability to modify a previously learned behavior in response to a change in reinforcement contingencies. The ability of xanomeline and varenicline to remediate the disruptive effects of scopolamine was compared between dominant and subordinate monkeys, with lighter and heavier drinking histories, respectively. We hypothesized that subordinate monkeys would be more sensitive to all three drugs. Scopolamine dose-dependently impaired performance on the serial SDR task in all monkeys at doses lower than those that produced non-specific impairments (e.g, sedation); its potency did not differ between dominant and subordinate monkeys. However, both AChR agonists were effective in remediating the scopolamine-induced deficit in subordinate monkeys, but not in dominant monkeys. These findings suggest xanomeline and varenicline may be effective for enhancing cognitive flexibility in individuals with a history of heavy drinking. Significance Statement Pro-cognitive effects of two acetylcholine (Ach) receptor agonists were assessed in group-housed monkeys who had several years’ experience drinking ethanol. The muscarinic ACh receptor agonist xanomeline and the nicotinic ACh receptor agonist varenicline reversed a cognitive deficit induced by the muscarinic ACh receptor antagonist scopolamine. However, this effect was observed only in lower-ranking (subordinate) monkeys and not higher-ranking (dominant monkeys). Results suggest that ACh agonists may effectively remediate alcohol-induced cognitive deficits in a subpopulation of those with alcohol use disorder.

10 April 2021 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
ATAaron M. Tryhus
Aaron M. Tryhus
PEPhillip M. Epperly
Phillip M. Epperly
ADApril T. Davenport
April T. Davenport
LGLindsey Galbo
Lindsey Galbo
PCPaul Czoty
Paul Czoty

28 July 2025 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
LCLawrence M. Carey
Lawrence M. Carey
LGLindsey Galbo
Lindsey Galbo
DMDavid R. Maguire
David R. Maguire
CFCharles P. France
Charles P. France